Use of a phosphoTAC that degrades PI3Kα (ZM‐PI05) (Figure 6), an essential lipid kinase in the pathway of the PI3K–AKT, which is more significant in HER2‐amplified breast cancers, can be similarly significant (Zhong et al. 2024). This evidence concerns the gene ERBB2 and breast carcinoma.